Changing paradigms in dermatology: Nuclear hormone receptors

Clinics in Dermatology

Volumn 21, Issue 5, 2003, Pages 447-454

  Winterfield, Laura ^a   Cather, Jennifer ^b   Cather, John ^b   Menter, Alan ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ADAPELENE; ALITRETINOIN; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; BEXAROTENE; BEZAFIBRATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL PROPIONATE; CLOFIBRATE; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; ETRETIN; ETRETINATE; GLUCOCORTICOID RECEPTOR; ISOTRETINOIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID; RETINOID DERIVATIVE; ROSIGLITAZONE; TACALCITOL; TAZAROTENE; THYROXINE RECEPTOR; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR;

ACNE; ADRENAL INSUFFICIENCY; BASAL CELL CARCINOMA; BONE NECROSIS; CATARACT; CLINICAL TRIAL; DELAYED PUBERTY; DERMATOLOGY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOXICITY; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; GROWTH DISORDER; HAND DISEASE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; IMMUNE DEFICIENCY; MENTAL DISEASE; MUSCLE ATROPHY; OSTEOPOROSIS; PANCREATITIS; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN INFLAMMATION; SKIN IRRITATION; T CELL LYMPHOMA; TACHYPHYLAXIS;

EID: 0347479358     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2003.08.011     Document Type: Article

References (81)

1. Torma H., Karlsson T., Michaelsson G., et al. Decreased mRNA levels of retinoic acid receptor alpha, retinoid X receptor alpha and thyroid hormone receptor alpha in lesional psoriatic skin. Acta Derm Venereol. 80:2000;4-9.
2. Saurat J.H. Retinoids and psoriasis novel issues in retinoid pharmacology and implications for psoriasis treatment . J Am Acad Dermatol. 41:1999;82-86.
3. Pratt W.B. The role of heat shock proteins in regulating function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem. 268:1993;21455-21458.
4. Dittmar K.D., Pratt W.B. Folding of the GC receptor by reconstituted hsp90-based chaperone machinery. The initial hsp90. p60. hsp70-dependent step is sufficient for creating the steroid binding conformation. J Biol Chem. 207:1997;13047-13054.
5. Schneikert J., Hubner S., Martin E., et al. A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of GC receptor activity. J Cell Biol. 146:1999;929-940.
6. Horwitz K.B., Jackson T.A., Bain D.L., et al. Nuclear receptor coactivators and corepressors. Mol Endocrinol. 10:1996;1167-1177.
7. Beato M., Chalepakis G., Schauer M., et al. DNA regulatory elements of steroid hormones. J Steroid Biochem. 32:1989;737-747.
8. Meyer T., Carlstedt-Duke J., Starr D.B. A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene. J Biol Chem. 272:1997;30709-30714.
9. Drouin J., Sun Y.L., Chamberland M., et al. Novel GC receptor complex with DNA element of the hormone-repressed POMC gene. EMBO J. 12:1993;145-156.
10. Schule R., Rangarajan P., Kliewer S., et al. Functional antagonism between oncoprotein c-Jun and the GC receptor. Cell. 62:1990;1217-1226.
11. Tuckermann J.P., Reichardt H.M., Arribas R., et al. The DNA binding-independent function of the GC receptor mediates repression of AP-1 dependent genes in the skin. J Cell Biol. 147:1999;1365-1370.
12. De Bosscher K., Vanden Berghe W., Vermeulen L., et al. GCs repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA. 97:2000;3919-3924.
13. Kassel O., Sancono A., Kratzschmar J., et al. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 20:2001;7108-7116.
14. Barnes P.H. Molecular mechanisms of corticosteroids in allergic diseases. Allergy. 56:2001;928-936.
15. Cronstein B.N., Kimmel S.C., Levin R.I., et al. Corticosteroids are transcriptional regulators of acute inflammation. Trans Assoc Am Phys. 105:1992;25-35.
16. Cato A.C., Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays. 18:1996;371-378.
17. Karin M. New twists in gene regulation by glucocorticoid receptor is DNA binding dispensable? Cell. 93:1998;487-490.
18. Barnes P.J. Anti-inflammatory actions of glucocorticoids molecular mechanisms . Clin Sci (Lond). 94:1998;557-572.
19. Scheinman R.I., Gualberto A., Jewell C.M., et al. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol. 15:1995;943-953.
20. Radoja N., Komine M., Jho S.H., et al. Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Mol Cell Biol. 20:2000;4328-4339.
21. Reichardt H.M., Schutz G. GC signaling - multiple variations of a common theme. Mol Cell Endocrinol. 146:1998;1-6.
22. Kellendonk C., Tronche F., Reichardt H.M., et al. Mutagenesis of the glucocorticoid receptor in mice. J Steroid Biochem Mol Biol. 69:1999;253-259.
23. Reichardt H.M., Tronche F., Berger S., et al. . New insights into GC and mineralocorticoid signaling lessons from gene targeting . Adv Pharmacol. 47:2000;1-21.
24. Schacke H., Docke W.-D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 96:2002;23-43.
25. Reichardt H.M., Tuckermann J.P., Gottlicher M., et al. Repression of inflammatory responses in the absence of DNA-binding by the glucocorticoid receptor. EMBO J. 20:2001;7168-7173.
26. Belvisi M.G., Wicks S.L., Battram C.H., et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of an in vivo separation of transrepression from transactivation activity. J Immunol. 166:2001;1975-1982.
27. Coghlan M.J., Kym P.R., Elmore S.W., et al. Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor selective quinoline derivatives with prednisolone-equivalent functional activity . J Med Chem. 44:2001;2879-2885.
28. Perez P., Page A., Brano A., et al. Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. FASEB J. 15:2001;2030-2032.
29. Oikarinen A., Haapasaari K.M., Sutinen M., et al. The molecular basis of GC-induced skin atrophy topical GC apparently decreases both collagen synthesis and corresponding collagen mRNA level in human skin in vivo . Br J Dermatol. 139:1998;1106-1110.
30. Kolbe L., Kligman A.M., Schreiner V., et al. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol. 7:2001;73-77.
31. Sclafani A.P., Gordon L., Chadha M., et al. Prevention of earlobe keloid recurrence with postoperative corticosteroids injections versus radiation therapy a randomized, prospective study and review of the literature . Dermatol Surg. 22:1996;569-574.
32. Kauh Y.C., Rouda S., Mondragon G., et al. Major suppression of pro-alpha I type I collagen gene expression in the dermis after keloid excision and immediate intrawound injection of triamcinolone acetonide. J Am Acad Dermatol. 37:1997;586-589.
33. Gras M.P., Verrecchia F., Uitto J., et al. Downregulation of human type VII collagen (COL7A1) promoter activity by dexamethasone. Exp Dermatol. 10:2001;28-34.
34. Price S.R., Du J.D., Bailey J.L., et al. Molecular mechanisms regulating protein turnover in muscle. Am J Kidney Dis. 37:(suppl):2001;S112-114.
35. Feldman, SR, Salam, TN, Rapp, SR. Quantitative assessment of psoriasis patients' preference for foam vehicle. Presented at AAD 2001: Washington, DC.
36. Bergstrom, K, Arambula, K, Kimball, AB. A randomized single-blind study of clobetasol propionate foam 0.05% compared to a combined program of solution and cream in the treatment of psoriasis. Presented at AAD 2002: New Orleans, LA.
37. Kligman A.M., Fulton J.E., Peiwig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 99:1969;469-476.
38. Peck G.L., Olsen T.G., Yoder F.W., et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med. 300:1979;329-333.
39. Nagpal S., Chandratina R.A. Recent developments in receptor-selective retinoids. Curr Pharm Des. 6:2000;919-931.
40. Tom, W, Peng, DH, Hata, T. Effect of short-contact topical tretinoin therapy on lower extremity ulcers in diabetic patients. Presented at International Investigative Dermatology 2003: Miami, Florida.
41. Scheth, P, Breneman, D, Stevens, V, et al Severe hand dermatitis is responsive to topical bexarotene 1% get. Presented at International Investigative Dermatology 2003: Miami, Florida.
42. Look J., Lanwehr J., Bauer F., et al. Marked resistance of RAR gamma-deficient mice to the toxic effects of retinoic acid. Am J Physiol. 269:1995;E91-98.
43. Chandraratna R.A. Future trends a new generation of retinoids . J Am Acad Dermatol. 39:1998;S149-152.
44. Chandraratna R.A. Rational design of receptor-selective retinoids. J Am Acad Dermatol. 39:1998;S124-128.
45. Saurat J.H. Retinoids and psoriasis novel issues in retinoid pharmacology and implications for psoriasis treatment . J Am Acad Dermatol. 41:1999;S2-6.
46. Chandraratna R.A. Tazarotene - first of a new generation of receptor-selective retinoids. Br J Dermatol. 135:(Suppl 49):1996;18-25.
47. Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol. 43:2000;S43-46.
48. Kaidbey K., Kopper S.C., Sefton J., et al. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol. 40:2001;468-471.
49. Peris K., Fargnoli M.C., Chimenti S. Preliminary observation on the use of topical tazarotene to treat basal cell carcinoma. N Engl J Med. 341:1999;1767-1768.
50. Shroot B., Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 36:(6 Pt 2):1997;S96-103.
51. Chen S., Ostrowski J., Whiting G., et al. Retinoic acid receptor gamma mediates topical retinoid efficacy and irritation in animal studies. J Invest Dermatol. 104:1995;779-783.
52. Thacher S.M., Vasudevan J., Chandraratna R.A. Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 6:2000;25-58.
53. Hashimoto Y, Shudo K. Retinoids and their nuclear receptors. Cell Biol Rev 1991;25:209-35.
54. Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002 May;8:1234-40.
55. Reichrath J., Munssinger T., Kerber A., et al. In situ detection of retinoid-X-receptor expression in normal and psoriatic human skin. Br J Dermatol. 133:1995;168-175.
56. Bershad S. Developments in topical retinoid therapy for acne. Semin Cutan Med Surg. 20:2001;54-61.
57. th World Congress of Dermatology, July 4, 2002: Paris, France.
58. Nathieu C., Adorini L. The coming of age of 1, 25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med. 8:2002;174-179.
59. Nagpal S., Lu J., Boehm M.F. Vitamin D analogs mechanism of action and therapeutic applications . Curr Med Chem. 8:2001;1661-1679.
60. Masood R., Nagpal S., Zheng T., et al. Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 96:2000;3188-3194.
61. Cunningham B.B., Landells I.D., Langman C., et al. Topical Calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 39:(2 Pt 1):1998;211-215.
62. Kragballe K, Steijlen PM, Ibsen HH, et al. Efficacy, tolerability and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol 1995 May;131:556-60.
63. Van de Kerkhof. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol 1995;132:675-82.
64. Veien N.K., Bjerke I., Jakobsen H.B. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol A double-blind trial. Br J Dermatol. 137:1997;581-586.
65. Barker J.N., Ashton R.E., Marks R., et al. Topical maxacalcitol for the treatment of psoriasis vulgaris a placebo-controlled, double-blind, dose-finding study with active comparator . Br J Dermatol. 141:1999;274-278.
66. Ashcroft D.M., Po A., Williams H.C., et al. Combination regimens of topical Calcipotriene in chronic plaque psoriasis. Arch Dermatol. 136:2000;1536-1543.
67. Guenther L., Van de Kerkhof P.C., Snellman E., et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris in a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 147:2002;316-323.
68. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of Calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003 Jan;48:48-54.
69. Rosen E.D., Sarraf P., Troy A.E., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 4:1999;611-617.
70. Ueda, E, Nakajima, T, Kishimoto, S, et al Down-regulation of cyclin A in squamous cell carcinoma line SCC13 by PPAR-selective ligand. Presented at International Investigative Dermatology 2003: Miami, Florida.
71. Rosenfield R.L., Deplewski D., Green M.E. Peroxisome proliferator- activated receptors and skin development. Horm Res. 54:2000;269-274.
72. Westergaard M., Henningsen J., Svendsen M.L., et al. Modulation of keratinocytes gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol. 116:2001;702-712.
73. Ellis C.N., Varani J., Fisher G.J., et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocytes proliferation . Arch Dermatol. 136:2000;609-616.
74. Sheu M.Y., Fowler A.J., Kao J., et al. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol. 118:2002;94-101.
75. Klippenberger S., Loitach S.M., Grundmann-Kollman M., et al. Activators of peroxisome proliferator activated receptors protect human skin from unltraviolet-B-induced inflammation. J Invest Dermatol. 117:(6):2001;1430-1436.
76. Tomic M., Jian C.K., Epstein H.S., et al. Nuclear receptors for retinoic acid and thyroid hormone regulate transcription of keratin genes. Cell Regul. 1:1990;965-973.
77. Ahsan M.K., Urano Y., Kato S., et al. Immunohistochemical localization of thyroid hormone nuclear receptors in human hair follicles and in vitro effect of L-triiodothyronine on cultured cells of hair follicles and skin. J Med Invest. 44:1998;179-184.
78. Billoni N., Buan B., Bautier B., et al. Thyroid hormone receptor beta1 is expressed in the human hair follicle. Br J Dermatol. 142:2000;645-652.
79. Kuenzli S., Saurat J.H. Effect of Topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study. Dermatology. 205:2003;252-256.
80. Safer J.D., Fraser L.M., Ray S., Holick M.F. Topical triiodothyronine stimulates epidermal proliferation, dermal thickening, and hair growth in mice and rats. Thyroid. 11:2001;717-724.
81. Dessein P.H., Morrison R.C., Lamparelli R.D., et al. Triiodothyronine treatment for Raynaud's phenomenon a controlled trial . J Rheumatol. 17:1990;1025-1028.